(Q43818100)

27 November 2017

Experience of nevirapine use in a London cohort of HIV-infected pregnant women (English)

1 reference

27 November 2017

1 reference

1 reference

1 reference

Edwards SG

1

1 reference

27 November 2017

Larbalestier N

2

1 reference

27 November 2017

Hay P

3

1 reference

27 November 2017

de Ruiter A

4

1 reference

27 November 2017

Welch J

5

1 reference

27 November 2017

Taylor GP

6

1 reference

27 November 2017

Easterbrook P

7

1 reference

27 November 2017

1 April 2001

1 reference

27 November 2017

1 reference

27 November 2017

2

1 reference

27 November 2017

2

1 reference

27 November 2017

89-91

1 reference

Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group

27 November 2017

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2001.00059.X

Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group P

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2001.00059.X

Safety profile of nevirapine, a nonnucleoside reverse transcriptase inhibitor for the treatment of human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2001.00059.X

Pharmacological implications of lengthened in-utero exposure to nevirapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2001.00059.X

The association between maternal HIV infection and perinatal outcome: a systematic review of the literature and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1293.2001.00059.X

10.1046/J.1468-1293.2001.00059.X

21 January 2018

Identifiers

DOI

1 reference

27 November 2017

1 reference